Table 2.
Overview of the characteristics of included studies
| First author (year) | Country | Population | Targeted process | Main outcomes | No. of participants surveyed | Type of participants | No. of medicines analysed | Study design |
|---|---|---|---|---|---|---|---|---|
| Patel (1985) [10] | Canada | CD | Prescription | Development of a gluten-containing medicines database and manufacturers of gluten-free products | 73 | Manufacturers | 103 | Descriptive study |
| Challen (1987) [11] | Australia | CD | Prescription | Development of a gluten-containing medicines database and manufacturers of gluten-free products | 68 | Manufacturers | 214 | Descriptive study |
| Miletic (1994) [20] | US | CD | Prescription and dispensation | Development of a dot blot assay for identification of gliadin presence in medicines | 0 | NA | 59 | Non-randomised experimental study |
| Crowe (2001) [17] | US | CD | Prescription | Development of a gluten-containing medicines database and manufacturers of gluten-free products | 105 | Manufacturers | 340 | Descriptive study |
| Mangione (2008) [7] | US | CD/DH | Dispensation | Review of the epidemiology, pathophysiology, diagnosis, treatment, and complications of celiac disease, in order to provide guidance to pharmacists | 0 | NA | 0 | Discussion paper |
| King (2009) [12] | US | CD | Prescription | Development of a database of manufacturers of gluten-free products | 122 | Manufacturers | 0 | Descriptive study |
| King (2009) [13] | US | CD | Prescription | Follow-up of a previous database of manufacturers of gluten-free products | 75 | Manufacturers | 200 | Descriptive study |
| King (2010) [16] | US | CD | Prescription | Follow-up of a previous database of manufacturers of gluten-free products | 121 | Manufacturers | 0 | Descriptive study |
| Mangione (2011) [18] | US | CD | Dispensation | Review of the aetiology, clinical manifestations, diagnosis, management and presence of gluten in medicines, in order to provide guidance to pharmacists | 0 | NA | 0 | Discussion paper |
| King (2013) [14] | US | CD | Prescription | Development of a gluten-containing medicines database | 91 | Manufacturers | 200 | Descriptive study |
| Jay (2014) [21] | US | CD/NCGS | Prescription and dispensation | Analysis of medicines suspected of causing adverse effects to determine gluten content | 5623 | Patients | 39 | Non-randomised experimental study / Survey |
| Cruz (2015) [15] | US | CD | Prescription | Development of a gluten-containing medicines database | 45 | Manufacturers | 84 | Descriptive study |
| Avena-Woods (2018) [19] | US | CD | Dispensation | Evaluation of the extent of community pharmacists’ self-assessment and actual knowledge of CD | 418 | Pharmacists | 0 | Survey |
CD celiac disease, DH dermatitis herpetiformis, NA not applicable, NCGS non-celiac gluten sensitivity, US The United States